Eli Lilly and Company===Tirzepatide
Tracked across 3 events · 33 articles · First seen Feb 05, 2026 · Last active Apr 03, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Regulatory
Eli Lilly and Company===Tirzepatide, a GLP-1 medication from Eli Lilly and Company, is being widely sought after for cosmetic weight loss in India, despite being approved for specific medical indications. Its sales have doubled, but its misuse is a growing concern for regulators.
Apr 03, 2026 · 8 articles
Tech
Eli Lilly and Company===Tirzepatide, a tirzepatide drug, is identified as a GLP-1 medication whose cardiovascular benefits are diminished or reversed upon discontinuation. The study's emphasis on continuous treatment could influence prescribing patterns and patient expectations.
Mar 18, 2026 · 7 articles
Regulatory
Eli Lilly and Company===Tirzepatide (tirzepatide) was also examined in the study and found to have no increased risk of NAION. This could be a positive for Eli Lilly and Company===Tirzepatide as it differentiates itself from semaglutide drugs regarding this specific side effect.
Feb 05, 2026 · 18 articles
NEWSDESK
Track Eli Lilly and Company===Tirzepatide live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard